Abstract
The balance between T helper (h)1 and Th2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th1 cytokines [interleukin (IL-2) and interferon (IFN-γ)] have been demonstrated to mediate the antiviral immune response. Serum levels of Th1 cytokines (IL-2 and IFN-γ) as well as of Th2 products (IL-4 and IL-10) were determined in a group of HCV-positive patients before and after treatment with IFN-α and Ribavirin (RIB). Results indicate that responder patients exhibited increased levels of IFN-γ and IL-10, while this enhancement was not observed in non-responder patients. In this respect, the major effect exerted by the combined therapy with IFN-α / RIB could be represented by the attainment of a re-equilibrium between inflammatory (Th1) and antiinflammatory (Th2) mechanisms. In this framework, according to current literature, novel therapeutical approaches to treat HCV infection are represented by administration of recombinant IL-2 and IL-10.
Keywords: ifn, ribavirin, responsiveness, gamma, interleukin, recombinant interleukin
Current Pharmaceutical Design
Title: Modifications of the Immune Responsiveness in Patients with Hepatitis C Virus Infection following Treatment with IFN-α / Ribavirin
Volume: 8 Issue: 11
Author(s): L. Amati, L. Caradonna, T. Magrone, M. L. Mastronardi, R. Cuppone, R. Cozzolongo, O. G. Manghisi, D. Caccavo, A. Amoroso and E. Jirillo
Affiliation:
Keywords: ifn, ribavirin, responsiveness, gamma, interleukin, recombinant interleukin
Abstract: The balance between T helper (h)1 and Th2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th1 cytokines [interleukin (IL-2) and interferon (IFN-γ)] have been demonstrated to mediate the antiviral immune response. Serum levels of Th1 cytokines (IL-2 and IFN-γ) as well as of Th2 products (IL-4 and IL-10) were determined in a group of HCV-positive patients before and after treatment with IFN-α and Ribavirin (RIB). Results indicate that responder patients exhibited increased levels of IFN-γ and IL-10, while this enhancement was not observed in non-responder patients. In this respect, the major effect exerted by the combined therapy with IFN-α / RIB could be represented by the attainment of a re-equilibrium between inflammatory (Th1) and antiinflammatory (Th2) mechanisms. In this framework, according to current literature, novel therapeutical approaches to treat HCV infection are represented by administration of recombinant IL-2 and IL-10.
Export Options
About this article
Cite this article as:
Amati L., Caradonna L., Magrone T., Mastronardi L. M., Cuppone R., Cozzolongo R., Manghisi G. O., Caccavo D., Amoroso A. and Jirillo E., Modifications of the Immune Responsiveness in Patients with Hepatitis C Virus Infection following Treatment with IFN-α / Ribavirin, Current Pharmaceutical Design 2002; 8 (11) . https://dx.doi.org/10.2174/1381612024607036
DOI https://dx.doi.org/10.2174/1381612024607036 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From TGF-β to Cancer Therapy
Current Drug Targets Advances in Microbiome Detection Technologies and Application in Antirheumatic Drug Design
Current Pharmaceutical Design Suppression of Protein Aggregation by L-Arginine
Current Pharmaceutical Biotechnology Ischemic Neuronal Damage
Current Pharmaceutical Design Nanochemistry-Based Immunotherapy for HIV-1
Current Medicinal Chemistry Biomarkers of Alzheimer’s Disease: An Overview of the Recent Inventions
Recent Patents on Biomarkers Astrocyte Influences on Ischemic Neuronal Death
Current Molecular Medicine PRISMA Based Systematic Review: Pharmacognostic Study of <i>Zanthoxylum armatum</i> DC.
Mini-Reviews in Medicinal Chemistry Insights into the Zinc-Dependent Deacetylase LpxC: Biochemical Properties and Inhibitor Design
Current Topics in Medicinal Chemistry Erythropoietic Porphyrias: Animal Models and Update in Gene-Based Therapies
Current Gene Therapy Pharmaceutical Mixtures: Still A Concern for Human and Environmental Health
Current Medicinal Chemistry Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Hypoxia in Pre-Eclampsia: Cause or Effect?
Current Women`s Health Reviews Stress-Induced Oxidative Changes in Brain
CNS & Neurological Disorders - Drug Targets Remyelination in Multiple Sclerosis: The Therapeutic Potential of Neural and Mesenchymal Stem/Progenitor Cells
Current Signal Transduction Therapy HSP60 is a Ubiquitous Player in the Physiological and Pathogenic Interactions between the Chaperoning and the Immune Systems
Current Immunology Reviews (Discontinued) Dengue Fever: Theories of Immunopathogenesis and Challenges for Vaccination
Inflammation & Allergy - Drug Targets (Discontinued) Hypothalamic Pituitary Adrenal Axis and Prolactin Abnormalities in Suicidal Behavior
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Aging and Immune-Mediated Diseases (Guest Editors: Christian Dejaco, Christina Duftner and Michael Schirmer)]
Current Immunology Reviews (Discontinued) Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of Osteosarcoma
Current Cancer Drug Targets